Company news

Prelude Therapeutics Incorporated news in 2026

Prelude Therapeutics Incorporated's news releases, calls and decks from 2026, newest first.

View company

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

October 16, 2026

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

October 13, 2026

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 11, 2026

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

September 10, 2026

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

April 20, 2026

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

April 14, 2026

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

March 16, 2026

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

March 9, 2026

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

February 3, 2026

Decks in 2026